Search Results 111-120 of 19890 for Melanoma
Research collaborators can contact the Markovic Melanoma Research Lab at Mayo Clinic for information about research partnerships.
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) ... melanoma. Participation eligibility. Participant ...
The Markovic Melanoma Research Lab at Mayo Clinic investigates immune homeostasis, platform nanomedicines, and novel vaccine strategies and adjuvants for ...
Melanoma is deadly and it's on the rise, particularly among teens and young adults. Research shows it's up eightfold among women and fourfold among young ...
Carter was given a relatively new immunotherapy drug, called pembrolizumab. "Fundamentally, in the treatment of metastatic melanoma, it's a three-pronged attack ...
The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of ...
The Markovic Melanoma Research Lab at Mayo Clinic brings together a strong team of oncologists, dermatologists and surgeons also engaged in melanoma ...
... melanoma in high risk families. Individuals who are affected with pancreas cancer and melanoma, as well as those without either cancer who have been ...
... melanoma. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.